Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma.

Next Previous
Search
Trial Profile

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Silmitasertib (Primary)
  • Indications Breast cancer; Colorectal cancer; Giant lymph node hyperplasia; Head and neck cancer; Lung cancer; Multiple myeloma; Prostate cancer; Renal cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 07 Feb 2013 New source identified and integrated (Mayo Clinic; 08-007659).
    • 06 Jun 2011 Interim results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 18 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top